About this Journal Submit a Manuscript Table of Contents
Sarcoma
Volume 2013 (2013), Article ID 439213, 7 pages
http://dx.doi.org/10.1155/2013/439213
Clinical Study

Outcome of Rhabdomyosarcoma in First Year of Life: Children’s Cancer Hospital 57357 Egypt

1Department of Pediatric Hematology/Oncology, Children’s Cancer Hospital Egypt 57357 (CCHE), 1 Seket El-Emam, Sayeda Zeinab, Cairo 11441, Egypt
2Departmrent of Surgical Pathology, Children’s Cancer Hospital Egypt 57357 (CCHE), 1 Seket El-Emam, Sayeda Zeinab, Cairo 11441, Egypt
3Department of Surgery, Children’s Cancer Hospital Egypt 57357 (CCHE), 1 Seket El-Emam, Sayeda Zeinab, Cairo 11441, Egypt
4Department of Radiotherapy, Children’s Cancer Hospital Egypt 57357 (CCHE), 1 Seket El-Emam, Sayeda Zeinab, Cairo 11441, Egypt
5Department of Radiodiagnosis, Children’s Cancer Hospital Egypt 57357 (CCHE), 1 Seket El-Emam, Sayeda Zeinab, Cairo 11441, Egypt
6Department of Research, Children’s Cancer Hospital Egypt 57357 (CCHE), 1 Seket El-Emam, Sayeda Zeinab, Cairo 11441, Egypt

Received 18 March 2013; Revised 12 June 2013; Accepted 24 June 2013

Academic Editor: Charles Catton

Copyright © 2013 Enas El Nadi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in children. Fifty percent of RMS cases occur in the first 10 years of life and less commonly in infants younger than one-year old. These infants require adapted multimodality treatment approaches. Patients and Methods. We analyzed patients’ characteristics, treatment modalities, and the outcome for RMS infants treated at Children’s Cancer Hospital Egypt (CCHE) between July 2007 and December 2010 and compared them to patients above one year treated on the same protocol. Results. Out of the 126 RMS treated during this period, 18 were below the age of one year. The male: female ratio was 1.25 : 1. The median age at diagnosis was 0.7 ± 0.2 years. Most of the cases (27.8%) were presented in head and neck regions. The estimated 4-years failure-free survival and overall survival for infants were 49 ± 12% and 70 ± 12%, respectively. These failure-free survival rate and overall survival rate did not differ from those for older patients ( ). Conclusion. Infants with RMS are a unique group of RMS who needs special concerns in tailoring treatment in addition to concerns regarding toxicity and morbidity in infants.